Immunogenic compositions comprising
The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis , and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis , and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.
1. A method for inducing an immune response against Lawsonia intracellularis bacterium to protect against porcine proliferative enteropathy (PPE) and an immune response against at least one additional pathogenic swine microorganism, comprising:
administering to a non-human animal a pharmaceutical composition comprising antigens which consist essentially of: (i) killed Lawsonia intracellularis bacterium, (ii) killed Mycoplasma hyopneumoniae , and (iii) Porcine circovirus.
2. The method of claim 1 , wherein the pharmaceutical composition is administered in one dose.
3. The method of claim 1 , wherein the pharmaceutical composition is administered in multiple doses.
4. The method of claim 3 , wherein a first dose of the pharmaceutical composition is administered when the non-human animal is about 2 to about 8 weeks of age.
5. The method of claim 4 , wherein a second dose of the pharmaceutical composition is administered about 1 to 4 weeks after the first dose.
6. The method of claim 1 , wherein the pharmaceutical composition contains 10<2> to 10<9> TCID50 of each antigen.
7. The method of claim 1 , wherein the pharmaceutical composition comprises between 5 and 5000 micrograms of each antigen.
8. The method of claim 1 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
9. The method of claim 8 , wherein the pharmaceutically acceptable carrier is an adjuvant.
10. The method of claim 9 , wherein said adjuvant is selected from a water-in-oil emulsion, an oil-in-water emulsion, and a water-in-oil-in-water emulsion.
11. The method of claim 2 , wherein the pharmaceutical composition is administered when the non-human animal is about 2 to about 8 weeks of age.